Annular choroidal detachment following intravitreal aflibercept injection in a patient with nivolumab treatment: a case report

BMC Ophthalmology

Case Report

Ryuki Fukumoto¹  Hirohisa Kubono¹  Yoshiko Ofuji¹  Saki Sakakura¹  Kotaro Suzuki¹  Takashi Nagamoto¹  Mari Kawamura¹  Kazuya Yamashita¹  Maho Sato²  Seiichiro Hata³ 

[1] Department of Ophthalmology, Keiyu Hospital, 3-7-3 Minatomirai, Nishiku, Yokohama, Kanagawa, Japan;Department of Ophthalmology, Keiyu Hospital, 3-7-3 Minatomirai, Nishiku, Yokohama, Kanagawa, Japan;Department of Ophthalmology, Keio University, Tokyo, Japan;Yokohama Sky Eye Clinic, Yokohama, Kanagawa, Japan;

关键词: Immune checkpoint inhibitor;    PD-1;    Choroidal detachment;    Vogt-Koyanagi-Harada disease;    Anti-VEGF antibody;   

DOI  :  10.1186/s12886-022-02714-2

 received in 2022-03-16, accepted in 2022-11-26,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundTo present a novel case that developed annular choroidal detachment after intravitreal anti-vascular endothelial growth factor antibody injection in a patient after immune checkpoint inhibitor treatment.Case presentationA 58-year-old Japanese man presented visual impairment in the right eye. Ophthalmological examination revealed macular edema in the right eye, which suggested the possibility of age-related macular degeneration. Following the intravitreal aflibercept injection, the annular choroidal detachment was observed in the injected eye. As hypotony or thick sclera was not observed, choroidal detachment seemed to have appeared due to enhanced inflammation by intravitreal injection. The patient had a history of stage IV paranasal cavity cancer and was treated with nivolumab, an immune checkpoint inhibitor. The immune response might have been enhanced due to the use of nivolumab so that intravitreal injection triggered inflammation. Three weeks after sub-tenon injection of triamcinolone acetonide, macular edema and choroidal detachment improved.ConclusionsIntravitreal aflibercept injection caused annular choroidal detachment in our patient, presumably because the immune system was activated after nivolumab treatment. To the best of our knowledge, this is the first case report of annular choroidal detachment that developed after intravitreal injection in a patient with a history of nivolumab therapy. With the increasing use of immune checkpoint inhibitors in patients with various cancers, clinicians should be aware of these potentially associated immune-related adverse events.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

Fig. 3

Fig. 2

Fig. 2

Fig. 1

Fig. 3